New Biologic Drug Shows Promise in Treating Osteoarthritis

Overview of Biologic Drugs in Arthritis Treatment

For several years, biologic drugs, particularly monoclonal antibodies, have been standard treatments for rheumatoid arthritis. In contrast, osteoarthritis has generally been managed with pain relief, oral anti-inflammatory medications, and localized injections to alleviate joint inflammation. The differing treatment approaches stem from the understanding of the underlying disease mechanisms; rheumatoid arthritis is classified as an autoimmune disease, while osteoarthritis was traditionally viewed as a consequence of wear and tear.

Recent advancements in understanding osteoarthritis have revealed a significant inflammatory component, which is mediated by many of the same signaling proteins involved in rheumatoid arthritis. This revelation has prompted a renewed focus on biologic drugs as potential treatments for osteoarthritis.

Canakinumab: A New Hope for Osteoarthritis

A recent study published in the *Annals of Internal Medicine* examined the clinical trial data for canakinumab, a biologic drug previously used to treat auto-inflammatory diseases. This drug targets interleukin-1 beta (IL-1B), a signaling molecule found in elevated levels in various auto-inflammatory conditions. Emerging evidence suggests that IL-1B may also have a role in the progression of osteoarthritis.

Osteoarthritis often leads to progressive joint degeneration, with many patients ultimately requiring total knee replacements (TKR) or total hip replacements (THR). The study utilized the rate of these replacements as a marker of disease progression.

Study Design and Results

The trial included over 10,000 participants across 1,091 sites in 39 countries. Participants were randomly assigned to receive either a placebo or one of three doses of canakinumab through subcutaneous injections every three months. Given that osteoarthritis typically progresses slowly, the study featured a substantial follow-up period, with a median duration of 3.7 years.

Results showed that all three doses of canakinumab reduced the risk of total knee or hip replacement compared to the placebo group. In the pooled canakinumab group, the hazard ratio for THR/TKR was 0.58, indicating a significant reduction in replacement events. Additionally, there was a modest decrease in the occurrence of osteoarthritis-related adverse events among those receiving treatment.

Limitations of the Study

Despite these promising results, one major limitation of the study is the choice of outcome measure. While total knee or hip replacement serves as one indicator of disease progression, it does not reflect the daily disease experience. Factors such as healthcare systems, insurance coverage, and patients’ age and comorbidities can also influence the decision to proceed with THR/TKR. Moreover, the study did not provide information on structural joint outcomes, which are critical markers of progression.

Conclusion and Future Research

These findings are significant, particularly as there is currently no known drug treatment that effectively prevents disease progression in osteoarthritis. While further research is necessary to confirm the efficacy of canakinumab for osteoarthritis, the results from this exploratory analysis are highly encouraging.

Written by Michael McCarthy
1. Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement. Ann Intern Med. https://doi.org/10.7326/M20-0527